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A B S T R A C T
Purpose
Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic colorectal cancer
(CRC) patients. KRAS mutations account for approximately 30% to 40% patients who are not
responsive. The serine-threonine kinase BRAF is the principal effector of KRAS. We hypothesized
that, in KRAS wild-type patients, BRAF mutations could have a predictive/prognostic value.
Patients and Methods
We retrospectively analyzed objective tumor responses, time to progression, overall survival (OS),
and the mutational status of KRAS and BRAF in 113 tumors from cetuximab- or panitumumab-
treated metastatic CRC patients. The effect of the BRAF V600E mutation on cetuximab or
panitumumab response was also assessed using cellular models of CRC.
Results
KRAS mutations were present in 30% of the patients and were associated with resistance to
cetuximab or panitumumab (P  .011). The BRAF V600E mutation was detected in 11 of 79
patients who had wild-type KRAS. None of the BRAF-mutated patients responded to treatment,
whereas none of the responders carried BRAF mutations (P  .029). BRAF-mutated patients had
significantly shorter progression-free survival (P  .011) and OS (P  .0001) than wild-type
patients. In CRC cells, the introduction of BRAF V600E allele impaired the therapeutic effect of
cetuximab or panitumumab. Treatment with the BRAF inhibitor sorafenib restored sensitivity to
panitumumab or cetuximab of CRC cells carrying the V600E allele.
Conclusion
BRAF wild-type is required for response to panitumumab or cetuximab and could be used to select
patients who are eligible for the treatment. Double-hit therapies aimed at simultaneous inhibition
of epidermal growth factor receptor and BRAF warrant exploration in CRC patients carrying the
V600E oncogenic mutation.
J Clin Oncol 26:5705-5712. © 2008 by American Society of Clinical Oncology
INTRODUCTION
Patients with metastatic colorectal cancer (mCRC)
have a 5-year survival rate of less than 10%.1 Cetux-
imab and panitumumab, two monoclonal anti-
bodies (MoAb) targeting epidermal growth factor
receptor (EGFR), have recently entered clinical
practice andhaveproven tobe effective inproviding
clinical benefit in approximately 10% to 20% of
patients.2-5 Bothmolecules bind to the extracellular
domain of EGFR, thus leading to inhibition of its
downstream signaling. EGFR is a transmembrane
tyrosine kinase receptor that, on ligand binding,
triggers two main signaling pathways. These in-
clude the RAS-RAF-MAPK axis, which is mainly
involved in cell proliferation, and the PI3K-
PTEN-AKT pathway, which is mainly involved in
cell survival and motility.6 Cetuximab and panitu-
mumab are registered for mCRC patients whose
tumors express EGFR protein as determined by
immunohistochemistry. However, it has been
clearly demonstrated that this method is not pre-
dictive of treatment efficacy.2,3,7 On the contrary,
recent data indicate thatEGFR gene status evaluated
by fluorescent in situ hybridization or chromogenic
in situ hybridization may predict response to these
MoAbs.8-12 We and others have previously shown,
at the preclinical13 and clinical8-10,14-18 level, that the
presence ofmutatedKRAS alleles is an independent
predictive marker of anti-EGFR MoAb resistance.
On the basis of these results, the European Union
drug regulatory body, the European Medicines
Agency, has approved the use of panitumumabonly
for mCRC patients whose tumors display wild-type
KRAS.However, theoccurrenceofKRASmutations
only accounts for approximately 30% to 40% of
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nonresponsive patients.8-10,14,15 Therefore, the identification of addi-
tional genetic determinants of primary resistance to EGFR-targeted
therapies in colorectal cancers (CRCs) is important at least for two
reasons. The first is to prospectively identify patients who should not
receive either cetuximab or panitumumab, thus avoiding their expo-
sure to ineffective and expensive therapy. Second, understanding the
molecular basis of primary resistance to EGFR-targetedMoAb thera-
pies could allow the rationale design of alternative treatment strate-
gies. We hypothesized that, in the absence of KRAS mutations,
resistance to anti-EGFR treatments could be caused by alterations of
othermembers of the RAS-RAF-MAPKpathway. Using genetic anal-
ysis of mCRCs from cetuximab- or panitumumab-treated patients
and cellular models of CRC, we assessed whether BRAF mutations
affect the response to therapies based on EGFR-targeted MoAbs. Be-
cause BRAFmutations are linked tomicrosatellite instability (MSI), a
condition generally associated with better prognosis and resistance to
standard chemotherapy,19 we also investigated MSI in our cohort of
treated patients.
PATIENTS AND METHODS
Patient Population and Treatment Regimens
We retrospectively analyzed 113 patients with histologically confirmed
mCRC either at Ospedale Niguarda Ca’ Granda (Milan, Italy) or at the Insti-
tute of Pathology (Locarno, Switzerland). Patients evaluated in this studywere
selected based on evidence that treatment outcome could be attributable only
to administration of either panitumumab or cetuximab. Patients were en-
rolledonto clinical trials (64of 113patients; seeAppendix, onlineonly)3,5,20-23
or received panitumumab or cetuximab as per label indication. For patients
who experienced progression on irinotecan-based chemotherapy, cetuximab
was administered in combinationwith irinotecan at the same dose and sched-
ule previously used. In all patients, refractoriness to irinotecan was defined as
documented disease progression by comparison of computed tomography or
magnetic resonance imaging scans during or within 3months of receiving an
irinotecan regimen (administered for at least 6 weeks). Besides the earlier
mentioned inclusion criteria, the availability of a tumor sample qualitatively
and quantitatively suitable for molecular analyses was also a requirement for
being considered in the present study. All patients had EGFR expression in
their tumor specimens in 1% of malignant cells assessed by immunohisto-
chemistry with the Dako EGFR PharmDx kit (DakoCytomation, Glostrup,
Denmark). Patients’ baseline characteristics, disease stage, and number of
previous lines of therapy are listed in Table 1. Treatment was continued
until progressive disease (PD) or toxicity occurred, according to the stan-
dard criteria.24
Clinical Evaluation and Tumor Response Criteria
Clinical response was assessed every 6 to 8 weeks with radiologic exami-
nation (computed tomography or magnetic resonance imaging). The Re-
sponse Evaluation Criteria in Solid Tumors24 were adopted for evaluation,
and objective tumor response was classified as partial response (PR), stable
disease (SD), or PD. Patients with SDor PDwere defined as nonresponders.24
Two independent oncologists and radiologists verified, in a blinded manner,
the clinical response for all patients.
Molecular Analyses
Formalin-fixed, paraffin-embedded tumor blocks were reviewed for
quality and tumor content, and a single representative tumor block from each
patient, containing at least 70% of neoplastic cells, was selected. Genomic
DNAwas extracted as previously described.8
MSI
The status of MSI was assessed by the analysis of the microsatellite loci
included in the panel of Bethesda (BAT25, BAT26, D2S123, D5S346, and
D17S250), as previously reported.25MSI was confirmed by the presence of an
additional peak in tumor sample compared with normal paired tissue. MSI
was defined as being present whenmore than 30% of loci showed instability.
Mutational Analysis of KRAS and BRAF in Tumor Samples
We searched for KRAS and BRAF point mutations in exons 2 and 15,
respectively. These two exons include codons 12 and 13 of KRAS and codon
Table 1. Baseline Patient Characteristics by KRAS and BRAF Status
Characteristic
Mutant KRAS Mutant BRAF
Wild-Type KRAS and
BRAF Total
No. of Patients % No. of Patients % No. of Patients % No. of Patients %
No. of patients 34 30 11 10 68 60 113 100
Male sex 16 14 8 7 56 50 80 71
Baseline age, years
Median 64 63 62 63
Range 48-82 43-68 26-85 26-85
Site of primary disease
Colon 21 19 10 9 39 35 70 62
Rectum 13 12 1 1 29 26 43 38
Anti-EGFR MoAb
Cetuximab 12 11 3 3 21 19 36 32
Cetuximab plus chemotherapy 12 11 2 2 37 33 51 45
Panitumumab 10 9 6 5 10 9 26 23
Received prior adjuvant chemotherapy 31 27 10 9 59 52 100 88
No. of prior lines of chemotherapy
1 4 4 2 2 6 5 12 11
2 14 12 4 4 35 31 53 47
3 11 10 3 3 15 13 29 26
4 2 2 1 1 2 2 5 4
5 0 0 0 0 1 1 1 1
Abbreviations: EGFR, epidermal growth factor receptor; MoAb, monoclonal antibody.
Thirteen patients received cetuximab as front-line therapy.
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600ofBRAF,where the largemajority of themutations in these genesoccur, as
already reported.8,25 The list of primers used for mutational analysis is avail-
able from the authors on request. All samples were subjected to automated
sequencing by ABI PRISM 3730 (Applied Biosystems, Foster City, CA). All
mutated samples were confirmed twice, starting from independent polymer-
ase chain reactions.
Cellular Models, Cell Viability, Bromodeoxyuridine, and
Apoptosis Assays
Experimental procedures involving the use of cellularmodels have been
described in the Appendix.
Statistical Analysis
The objective tumor response was the end point of our exploratory
study. Qualitative comparisons of objective response to therapy (responders
[PR] v nonresponders [PD  SD]) and gene mutations as predictors were
performed by the two-tailed Fisher’s exact test to check possible significance.
The level of significancewas set atP .05. Theprogression-free survival (PFS)
and overall survival (OS) analysis were determined according to the Kaplan-
Meiermethod, and survival curveswere comparedusing the log-rank test. PFS
was defined as the time from start of treatment (see Patient Population and
Treatment Regimens) until first documented tumor progression or death.
Data were analyzed using the Stata 9.1 package (Stata Corp, College Sta-
tion, TX).
RESULTS
Mutational Profiling of KRAS and Response of
Patients Treated With Cetuximab or Panitumumab
The mutational status of KRAS was assessed in a cohort of 113
patients (41 females and 72males, with amean age 63 years) who had
received either panitumumab- or cetuximab-based chemotherapy.
Twenty-four patients (21%) achievedPR, and themediandurationof
responsewas25weeks (range, 10 to128weeks). Patient characteristics
by KRASmutational status are listed in Table 1. KRAS exon 2 muta-
tions were found in 34 (30%) of 113 analyzed patients. KRASmuta-
tions were detected in two (8%) of 24 responsive patients but in 32
(35%) of 89 nonresponders (Fig 1). The data confirm that the pres-
ence of KRAS mutations correlates with lack of response to anti-
EGFR MoAb therapy (two-tailed Fisher’s exact test, P  .011).
The follow-up analyses indicated that patients carrying a KRAS-
mutated tumor displayed a shorter PFS (log-rank test, P .0275;
Fig 2A).No statistically significant differences were observed byOS
analysis (P .0869; Fig 2B).
 KRAS mutational status
mCRC Patients Treated With Panitumumab or Cetuximab, N = 113
 BRAF mutational status
on Wild-Type KRAS tumors 
46/68 (68%)*11/11 (100%)*Nonresponders
22/68 (32%)*0/11 (0%)*Responders
Wild-Type BRAF
68/79 (86%)
Mutant BRAF
11/79 (14%)
*P < .05 (P = .029)
57/79 (72%)**32/34 (94%)**Nonresponders
22/79 (28%)**2/34 (6%)*Responders
Wild-Type KRAS
79/113 (70%)
Mutant KRAS
34/113 (30%)
**P < .05 (P = .011)
45%
28%
27%
Mutant KRASWild-Type KRAS
PR
32%
6%
62%
Wild-Type BRAF Mutant BRAF
73%
0%
27%
41%
32%
27%
PDSD
Fig 1. KRAS and BRAF mutations correlate with lack of response to treatment
with monoclonal antibodies targeting epidermal growth factor receptor. The
number of responders and nonresponders (stable disease [SD]  progressive
disease [PD]) is indicated according to KRAS or BRAF mutational status. The
percentage of patients displaying partial response (PR), SD, or PD is shown in the
pie charts. mCRC, metastatic colorectal cancer.
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Fig 2. KRAS mutations are associated with shorter progression-free survival
(PFS). (A) Patients with wild-type KRAS tumors displayed a better PFS than
patients with KRAS-mutated tumors (log-rank test, P  .0275). (B) Patients
carrying KRAS-mutated tumors tended to have shorter overall survival. However,
this difference did not reach statistical significance (log-rank test, P  .0869). ns,
not significant.
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Mutational Profiling of BRAF in Wild-Type KRAS
Patients Treated With Cetuximab or Panitumumab
We and others have previously reported that KRAS and BRAF
mutations are mutually exclusive in CRCs.26,27 This relationship was
experimentally verified in our sample set, and we found that none of
theKRAS-mutated samples carried concomitantBRAFmutations, or
vice versa. The only type of BRAFmutation found in our cohort was
thepreviouslydescribedV600E substitution,whichwasdetected in11
patients (13%). In all patients, the amino acid change was a result of
the classicGTG3GAGmutation at position 1799of theBRAFnucle-
otide sequence. Patient characteristics by BRAFmutational status are
listed in Table 1.
BRAF V600E Allele Impairs the Response to
Cetuximab or Panitumumab
The presence of BRAF mutations was inversely associated with
response to therapy (Fig 1). Significantly, none of 22KRASwild-type
patients who experienced PR displayed BRAFmutations, whereas 11
(14.0%) of 79 nonresponder patients carried the BRAFV600Emuta-
tion (two-tailed Fisher’s exact test, P .029). These data indicate that
occurrence of oncogenic BRAF alleles negatively interferes with the
clinical response toMoAbs targeting EGFR.
BRAF Mutations Are Associated With Shorter PFS
and OS
We assessed how the occurrence of BRAF mutations affected
clinical parameters such as PFS and OS. The follow-up analyses indi-
cated that within the subgroup of KRAS wild-type patients, those
carryingaBRAF-mutated tumorhada shorterPFSandOSthanBRAF
wild-type patients (log-rank test, P  .0010 and P  .0001, respec-
tively; Figs 3A and 3B). In the entire cohort of patients, independently
from KRAS mutational status, individuals with BRAF-mutated tu-
mors still displayed shorter PFS and OS than patients with BRAF
wild-type tumors (log-rank test, P  .0107 and P  .0001, respec-
tively; Figs 3C and 3D). This significant association indicates that the
presence of BRAF V600E mutation correlates with a worse prog-
nosis. MSI has been linked both to the occurrence of BRAFmuta-
tion and to improvedprognosis in sporadicCRCpatients treatedwith
fluorouracil-based regimens.19,28-30 MSI was assessed in a subset of
patients, including 10 with BRAF-mutated samples, 24 with KRAS-
mutated samples, and 41 with samples that were wild type for both
genes. We identifiedMSI in one (1.3%) of these 75 patients, and this
patient had a sample that was wild type for both KRAS and BRAF.
Importantly, none of the tested BRAF-mutated tumors displayed
MSI, indicating that this factor is unlikely to affect the OS results and
the effect on the efficacy of EGFR-targeted therapies presented earlier.
BRAF V600E Allele Impairs the Response of CRC Cells
to Cetuximab or Panitumumab
The genetic profiling of CRCs showed that the presence of mu-
tated BRAF negatively interferes with clinical response to EGFR-
targetedMoAbs.We hypothesized that oncogenic activation ofBRAF
by the V600E mutation could bypass (short circuit) the EGFR-
initiated signaling cascade. To assess the effect of the BRAF V600E
mutation on response to cetuximab or panitumumab, we used cellu-
lar models of CRC. Specifically, we used a CRC line, DiFi, carrying
amplification of the EGFR gene.8 We and others have previously
shown that the proliferation of DiFi cells is inhibited by nanomolar
concentration of cetuximab, and therefore, this line can be exploited
to understand the molecular and cellular basis of sensitivity to anti-
EGFR MoAb therapy.8,31 We verified that DiFi cells do not show
mutations in either KRAS or BRAF (data not shown), thus allowing
further functional experiments. We found that DiFi cells expressing
the mutated BRAF V600E allele (DiFi-BRAF) were less sensitive to
either cetuximab or panitumumab compared with parental cells
transducedwithanemptyvector (Figs4Aand4B).Thesedata indicate
that the presence of oncogenic BRAF (such as the V600E mutant)
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Fig 3. (A and B) In wild-type KRAS
patients, those carrying a BRAF-mutated
tumor had a shorter progression-free
survival (PFS) and overall survival (OS)
than wild-type BRAF patients (log-rank
test, P  .0010 and P  .0001, respec-
tively). (C and D) In the entire cohort of
patients, individuals with wild-type BRAF
tumors still displayed longer PFS and OS
than patients with BRAF-mutated tumors
(P  .0107 and P  .0001, respectively).
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impairs the therapeutic potential of cetuximab and panitumumab in
CRC cells.
To assess whether this finding could be replicated in cancer cells
in which the BRAFV600E was naturally present, we used HT-29 and
COLO-205,which are two cell lines derived fromcolorectal tumors in
which the mutation had been previously detected. After indepen-
dently verifying that both lines carried the BRAF V600E allele (and
were wild type for KRAS), we found that HT-29 and COLO-205 are
highly refractory to cetuximab and panitumumab treatment (Figs 4A
and 4B).
Combinatorial Targeting of EGFR and BRAF in CRC
Cells Carrying the BRAF V600E Allele
The mutational profiling of CRCs showed that the presence of
BRAFmutations renders cancer cells unresponsive to EGFR-targeted
MoAb therapies.We hypothesized that the pharmacologic inhibition
of BRAFmight restore the sensitivity to cetuximab or panitumumab
in CRC cells carrying the V600E mutation. Sorafenib, a clinically
approved small-molecule kinase inhibitor, was used to pharmacolog-
ically target BRAF.32
When DiFi-BRAF, COLO-205, and HT-29 cells were treated
with a combination of cetuximab and sorafenib, we found a dramat-
ically reduced viability in all three cellular models (Figs 4C, 4D, and
4E), whereas single agents, alone, had limited effects. To dissect the
mechanism through which the combinatorial treatment synergisti-
cally affected cancer cells carrying the BRAF V600E mutation, we
measured its effects both on cell cycle and on apoptosis. The combi-
nation of cetuximab and sorafenib limitedly affected proliferation
compared with sorafenib alone (Fig 5A), whereas it showed a
prominent proapoptotic effect, as demonstrated by the massive
increase of caspase 3/7 activation observed in HT-29 and COLO-
205 cells (Fig 5B).
DISCUSSION
Cetuximab and panitumumab have shown efficacy in approximately
10% to 20% of mCRC patients. It is now emerging that genetic
alterations of EGFR and its downstream signaling effectors may pre-
dict the efficacy of EGFR-targetedMoAbs.8-15 Inparticular, the role of
oncogenicKRAShas been extensively analyzed, leading to the conclu-
sion that the occurrence of KRAS mutations represents a predictive
marker of anti-EGFRMoAb resistance.8-10,13-17 However,KRASmu-
tations only account for 30% to 40% of nonresponsive patients.
Therefore, the identification of additional genetic determinants of
primary resistance to EGFR-targeted therapies in CRC is clearly a
priority. Genetic and biochemical evidence indicates that BRAF is the
principal downstream effector of KRAS.33,34 Whether and to what
extent the oncogenic activation of BRAF (a serine-threonine kinase
mutated in approximately 10% of CRCs) affects the response to anti-
EGFRMoAbs has been onlymarginally investigated.13 By analyzing a
larger cohort of mCRCs patients, we found that BRAFmutations are
associated with resistance to EGFR-targeted MoAb therapies. Our
data indicate that the role of BRAFmutations in patients treated with
EGFR-targeted drugs is similar to that played by mutated KRAS. We
propose that the combined mutational analysis of both KRAS and
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Fig 4. (A and B) The colorectal cancer cell line DiFi was transduced with either an empty vector or a BRAF V600E–encoding lentiviral vector. Cell viability was measured
after treatment with either cetuximab or panitumumab. (C to E) Viability of DiFi, COLO-205, and HT-29 cells after combinatorial treatment with cetuximab plus sorafenib.
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BRAF could be used to prospectively selectmCRCpatients eligible for
EGFR-targetedMoAb treatment, with evidentmedical and economic
implications.However, our findings need to be formally confirmed in
a randomized clinical trial comparing an experimental arm contain-
ing cetuximab or panitumumab with a control arm without this
targeted therapy.
Despite the predictive value of both KRAS and BRAF muta-
tions, in our cohort, there was still a significant percentage of
nonresponsive patients (41%) who did not have mutations in
either gene. Therefore, further molecular markers are needed to
better define patients who are unlikely to benefit from EGFR-
targeted MoAb treatment.
The present study also shows that patients carrying aBRAFpoint
mutation have a shorter PFS and OS. This is in accordance with
previousdata indicating thatCRCswithBRAFmutationshave amore
aggressive phenotype.28 It has been previously reported that BRAF
mutations are more frequently detected in MSI-sporadic CRC com-
pared with microsatellite-stable CRC (up to 50% v up to 12%,
respectively).28-30 Considering thatMSI is a condition generally asso-
ciated with better prognosis and with resistance to standard chemo-
therapies,19 we investigated this marker in our series. The tumors in
whichwedetectedBRAFmutationsdidnot showMSI, thus excluding
that the results could be a result of a general mechanism of MSI-
dependent drug resistance. Therefore, the prognostic and predictive
value of BRAFmutations in anti-EGFR–treated mCRC patients does
not depend on theMSI status. The frequency ofMSI in our cohort of
advanced CRC patients is significantly lower (1.3%) with respect to
the expected rate (at least 15%) when all stages of sporadic CRC are
analyzed.We analyzed 30 additionalmCRCpatients (not treatedwith
EGFR-targeted therapies), none of whom showed MSI. Therefore,
our cumulative results indicate that only one of 105 advanced CRC
patients showed MSI. A stage selection may account for these results
because our cohort included only metastatic patients. In fact, our
frequency is similar to that reported in a previous study that found
only five patients (2.7%)withMSI in 190mCRCpatients.35 Thus, our
results are well in accordancewith the notion that theMSI phenotype
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Fig 5. (A) Effects of combinatorial sor-
afenib plus cetuximab on proliferation by
measuring bromodeoxyuridine (BrdU) incor-
poration in HT-29 and COLO-205 cells. (B)
Levels of activated caspases 3/7 (apoptotic
markers) after combinatorial treatment. Re-
sults (average  standard deviation) were
normalized to untreated cells. C indicates
values for vehicle-treated (blue bars) or
cetuximab-treated (yellow, gray, and red
bars) cells. (*) P  .05; (**) P  .01; and
(***) P  .001 by Bonferroni multiple com-
parison test.
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is associated with better prognosis19 and with a reduced likelihood of
metastasis in patients with CRC.36
Although our study suggests a strong correlation ofBRAFmuta-
tions in mCRC with a worse prognosis, further studies are needed to
fully evaluate this marker with and without EGFR-targeted therapies,
similar to what has been done forKRAS.18
To assess, at the molecular level, how the BRAFmutation could
influence the response to anti-EGFR MoAbs, we exploited cellular
models of CRC. We found that the occurrence or the exogenous
introduction of the BRAF V600E allele in CRC cells dramatically
impairs their response to cetuximab or panitumumab. These results
have two relevant implications. First, they show that the presence of
theV600Ealleledirectly affects the response toEGFR-targetedMoAbs
at the cellular level. Second, they suggest that the correlation between
the occurrence ofBRAFmutation and the ineffective clinical response
to cetuximab or panitumumab is not generically a result of the poorer
prognosis of BRAF-mutated tumors. Our cell-based analysis also
shows that even BRAF-mutated CRC cells can potentially respond to
EGFR-targeted MoAbs if the BRAF inhibitor sorafenib is adminis-
tered concomitantlywith cetuximaborpanitumumab.Ofnote, either
drug alone had limited activity, indicating that they act synergistically.
These data indicate that in BRAF-mutated tumors, the therapeutic
effect of cetuximab or panitumumab could be restored by two-hit
approaches aimed at blocking the EGFR pathway at multiple loca-
tions. In addition to sorafenib, other compounds targeting either
BRAF (PLX4032) or its downstream effectors (ARRY-162, AZD6244,
andPD0325901) are in clinical development37 and could be exploited
in combination with EGFR-targetedMoAb therapy.
Overall, the present study has at least two implications that could
be relevant for the therapy of mCRC. The first is that patients whose
tumors bear theBRAFV600E allele are not likely to experience signif-
icant clinical benefit on either cetuximabor panitumumab treatment.
Therefore,BRAFmutationanalysis couldbeusedas anadditional tool
for the selection of mCRC patients who might benefit from EGFR-
targetedMoAb therapies. The second is that clinical trials designed to
testmultiple therapieswithEGFRandBRAF/MAPKinhibitors should
be conceived formCRCpatients inwhomtheKRAS/BRAFpathway is
oncogenically activated. Because cetuximab, panitumumab, and sor-
afenib are already approved for clinical use, the data presented here
could find immediate clinical evaluation in phase II trials in patients
who have BRAF-mutated tumors.
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Glossary Terms
BRAFV600E: The V600E is the most common oncogenic
mutation of BRAF in cancer. The V600E aminoacid change re-
sults in constitutive activation of the BRAF kinase and promotes
cell transformation.
PI3K-PTEN-AKT pathway: Signal transduction pathways
involving the signaling molecules phosphatidylinositol-3 kinase
(PI3K), PTEN and Akt. PI3K generates phosphorylated inositides at
the cell membrane which are required for the recruitment and acti-
vation of the serine kinase Akt. PTEN is a lipid phosphatase which
counteracts the effect of PI3K. Accordingly mutated PI3K and AKT
act as dominant oncogenes while PTEN is a tumor suppressor gene.
Cetuximab: Also called Erbitux or C225, cetuximab is a
monoclonal antibody that is designed to target EGFR and block
its signaling activity by initiating receptor activation.
Panitumumab: Also known as ABX-EGF, panitumumab is a
fully human immunoglobulin G2monoclonal antibody against
EGFR and inhibits ligand-induced activation of the EGFR. This anti-
body is generated frommouse strains engineered to be deficient in
mouse antibody production and to produce fully human antibodies.
KRAS: The gene that encodes K-Ras, a protein that is a
member of the small GTPase superfamily, in which a single
amino acid substitution results in an activating mutation. Al-
ternative splicing gives rise to variants encoding two isoforms
that differ in the C-terminal region.
BRAF: BRAF is an isoform of RAF. Raf proteins (Raf-1, A-Raf,
B-Raf) are intermediate to Ras and MAPK in the cellular prolifera-
tive pathway. Raf proteins are typically activated by Ras via phos-
phorylation, and activated Raf proteins in turn activate MAPK via
phosphorylation. However, Raf proteins may also be independently
activated by other kinases.
Sorafenib: A substance belonging to the family of drugs called raf
kinase inhibitors and anti-VEGF that is being studied in the treatment
of cancer.
MAPK (mitogen-activated protein kinase):MAPKs are a
family of enzymes that form an integrated network influencing cellular
functions such as differentiation, proliferation, and cell death. These
cytoplasmic proteins modulate the activities of other intracellular pro-
teins by adding phosphate groups to their serine/threonine amino acids.
MSI (microsatellite instability):Microsatellites are repeating
units of 1-4 DNA base pairs that are distributed widely throughout
the genome and have a high degree of repeat length variation in the
population. Their length remains stable with cell division and inheri-
tance so they may be used as molecular markers of cell lineage, in
population genetic studies or paternity testing. Defects in the genes
involved in DNA mismatch repair result in genomic instability that
may be detected as MSI, an alteration in the length of the microsatel-
lites from cell to cell.
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